Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer

Next Previous
Trial Profile

Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gamma tocotrienol (Primary) ; Pentoxifylline (Primary)
  • Indications Gastrointestinal disorders; Radiation-induced abnormalities
  • Focus Therapeutic Use
  • Acronyms PPALM

Most Recent Events

  • 01 Mar 2022 Status has been changed to discontinued, as per Results published in the Radiotherapy and Oncology
  • 01 Mar 2022 Results published in the Radiotherapy and Oncology
  • 25 Jul 2019 Planned End Date changed from 5 Jan 2019 to 30 Sep 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top